Deepak Nitrite — Spending the Cash Pile to Build a Chemicals Chain

The State of Play

Deepak Nitrite spent the last three years deliberately trading today’s profits for tomorrow’s scale. Once a famously debt-free, high-return chemicals maker, it is now in the thick of an ₹11,000 crore capital-spending programme to build an integrated chemicals chain — culminating in India’s first home-grown polycarbonate plant. The arithmetic of that choice is visible in the numbers: full-year profit has fallen four years running (₹1,067 crore in FY22 to ₹551 crore in FY26) and return on capital has slid from 44% to about 11%, even as the company laid down roughly ₹1,800 crore of half-finished plants and took on its first meaningful debt. The March 2026 quarter snapped back hard — 18% margins, profit doubling sequentially — but largely on a one-off bet on cheap raw materials, not yet on the new plants the whole strategy rests on.

The Company

Incorporated in 1970, Deepak Nitrite makes chemical intermediates — the building-block molecules that go into agrochemicals, dyes, pharmaceuticals, fuel additives, paints and plastics. The founder’s origin story is import substitution: replacing imported sodium nitrite in India. The business now runs in two halves, housed in three entities:

• Advanced Intermediates (the legacy standalone business) — nitrites, fuel additives, and agro/dye/pharma intermediates. This is the older, more cyclical leg.
• Phenolics (Deepak Phenolics) — phenol, acetone and isopropyl alcohol (IPA). By FY25 this had grown to over 70% of group revenue and become the profit engine.
• Deepak Chem Tech (DCT) — the new vehicle where all the fresh chemistry is being built: nitric acid, fluorination, MIBK/MIBC, and the flagship polycarbonate complex.

A structural point worth holding onto, because management repeats it on every call: the upstream-integration profits book inside DCT, so the standalone segment’s reported margins understate the true economics — “focus on the EBITDA of the group, not the standalone.”

Promoters hold a steady 49.33%, inching up gently with no selling. Below them, the notable shift is domestic institutions accumulating hard — from 15.6% to 23.5% over three years — buying what foreign funds (down to 6.2%) and the public have sold. The stock trades at about 41 times earnings despite returns being well off their highs.

The Story So Far

The thread running through three annual reports and four earnings calls is a single, consistent strategic choice — build an integrated, import-substituting chemicals complex through a brutal down-cycle — and the honest tension that comes with it: the spending is real and visible, the payoff keeps slipping to the right.

FY23 — a record year that already showed the squeeze

FY23 carried a valedictory note (founder C.K. Mehta passed away in July 2023) and a confident expansion message. Revenue crossed ₹8,000 crore for the first time (₹8,020 crore, +17%), but profit fell 20% to ₹852 crore — the year’s defining tension. Management blamed normalisation off an exceptional FY22, high input costs, and a 40-day fire outage at Nandesari. The headline forward move was an MoU with the Gujarat government for ~₹5,000 crore of greenfield projects in intermediates, phenol, acetone and bisphenol-A — “a big step towards making Bharat Aatmanirbhar,” in the CMD’s words. The balance sheet was net debt-free; the dividend was ₹7.50.

FY24 — “laying the building blocks”

The tone pivoted from harvesting a record to building for the future. Revenue actually slipped 4% to ₹7,682 crore and return on capital fell from 27% to 19%, yet the strategic narrative grew louder. Three milestones anchored the year: a second Gujarat MoU (₹9,000 crore for polycarbonate, MMA and aniline, taking the combined plan to roughly ₹14,000 crore), a binding propylene-supply term sheet with Petronet LNG, and the commissioning of a fluorination plant. Phenolics held up (revenue above ₹5,000 crore) despite phenol spreads compressing under “disproportionate imports”; Advanced Intermediates grew volumes but at subdued realisations. Still net debt-free, the company used its clean balance sheet as the war-chest for the build.

FY25 — “Destination Bharat,” and the balance sheet tilts

By FY25 the projects firmed from MoUs into costed reality, and the financial character changed. Revenue recovered 8% to ₹8,282 crore, but profit fell again to ₹697 crore and return on capital dropped to 14% — the third straight year of compression. Management now openly framed this as the cost of an “investment phase.” The flagship was named: India’s first fully integrated polycarbonate plant at Dahej, 165,000 tonnes a year, to be built by acquiring and relocating Trinseo’s polycarbonate plant from Stade, Germany. The China language sharpened markedly — overcapacity “reshaping the global chemical industry,” China running “nearly 100% of new phenol builds.” Crucially, the long debt-free era ended: net debt of ₹256 crore, borrowings climbing toward ₹1,770 crore, and capital-work-in-progress doubling to ₹1,649 crore as the Trinseo asset and the new plants moved onto the books.

Q1 FY26 (call of 14 August 2025) — orders delayed, not declined

Into the current year, the squeeze in Advanced Intermediates was acute. Agrochemical-intermediate customers were destocking, and Chinese oversupply pressed on prices. Management’s framing:

“Orders delayed are not orders declined.” — Maulik Mehta, then Executive Director & CEO

The segment’s EBIT margin sat at just 6%; Phenolics, at 8% and recovering off a multi-year-low base, carried the quarter. Management laid out the project calendar in detail: nitric acid online “by the end of Q2,” MIBK/MIBC in the second half, the ₹220 crore fluorochemicals plant by early 2026, and polycarbonate by December 2027. The total programme was now ~₹10,000–11,000 crore (with BPA), peak debt capped at ~₹7,000–7,500 crore and a debt-to-equity ceiling of 1.5x.

Q2 FY26 (call of 14 November 2025) — agrochem volumes “essentially zero”

The most striking disclosure of the year came here: key agrochem-intermediate volumes were “essentially 0 or close to 0” after four to five quarters of customer destocking — “conspicuously absent in our Q2 results.” First-half group EBITDA had fallen from ₹647 crore a year earlier to ₹438 crore. Phenolics again did the heavy lifting (a record IPA quarter). The integration assets were “expected to be fully operational in Q4 FY26,” and management promised “by June 2026, everything will be done.” Polycarbonate commissioning was reaffirmed for the January–March 2028 quarter.

Q3 FY26 (call of 13 February 2026) — an unusually candid mea culpa

Q3 was weaker than management had signalled, and Mehta said so plainly. Two reasons: nitric acid commissioning slipped to mid-December (technical “last-mile” issues), and rather than restrain supply, the company chose to stay aggressive and buy nitric acid at spot prices — deliberately compressing its own margins. Separately, a favourable US ruling removing anti-dumping duty on Deepak’s sodium nitrite was delayed by the US government shutdown, disrupting planned US sales. Advanced Intermediates’ material margin hit a 7–8 year low. The forward statement to check: “Q4 will be better than Q3, and Q1 FY27 better still.” MIBK/MIBC was now “within this quarter” (Q4).

Q4 FY26 (call of 18 May 2026) — the best quarter, on a clever feedstock bet

The March quarter delivered the year’s standout: group EBITDA up 74% sequentially to ₹383 crore, an 18% margin, profit doubling to ₹220 crore. But the candour continued — the surge rested largely on a deliberate procurement bet. In late January, watching US naval carriers converge “in a pincer movement” near the Middle East, Mehta anticipated volatility and bought benzene, toluene and xylene “at every dip,” carrying unusually large low-cost inventory into the new year. “That position has held out quite well.” The new plants, by contrast, were not yet the story: nitric acid ran at just ~45% utilisation in Q4 on technical issues, MIBK/MIBC slipped again to Q2 FY27, and polycarbonate commissioning drifted from December 2027 to June 2028. A China tailwind was flagged as real and “already happening” — a December 2025 Chinese guideline constraining hazardous chemistries, which favours responsible nitration players like Deepak.

The pattern across the four calls is worth stating cleanly, because it is the heart of an honest chronicle: the strategy is consistent and the spending is real, but the timelines keep slipping. Nitric acid went from “end of Q2” to “45% utilisation with technical issues” four quarters later. MIBK/MIBC slid from “H2 FY26” to “Q2 FY27.” Polycarbonate moved from December 2027 to June 2028. Meanwhile the dependable Phenolics business quietly compounded (segment EBIT rising ₹101 → 145 → 145 → 287 crore through the year) and paid for the wait.

Where Things Stand

As of the May 2026 call, Deepak Nitrite is mid-build and mid-cycle. The full year FY26 was, on the reported numbers, still a down year — revenue ~₹7,950 crore and profit ₹551 crore, both below FY25 — capping a four-year slide in profit and returns that traces directly to a soft agrochemical cycle, Chinese oversupply on intermediates, and the drag of a large capex programme not yet earning. Against that, the building blocks are landing one by one: nitric acid (still being stabilised), fluorination and nitration commissioned, an ₹11,000 crore integrated complex funded 60:40 debt-to-equity with bank lines tied up, and the Trinseo-sourced polycarbonate plant on track for June 2028. Management guides to a stronger FY27 — “Q1 FY27 better than Q4, return to the normalcy of a couple of years ago” — built on margin-accretive new products (commercial from Q3 FY27), the China hazardous-chemistry tailwind, and the integration finally flowing through. Whether the long-promised payoff arrives on the (repeatedly revised) schedule, and whether returns climb back toward the company’s own history, is what the build is ultimately a bet on. The dividend, notably, has stayed ₹7.50 throughout.

The Four Checks

1. Quality and moat. A competent operator in mostly commodity chemistry, which caps how good this business can be. The advantages are real but of the modest kind: India’s dominant phenol-acetone producer (two million tonnes of phenol made, plants run above 120% of rated capacity), full ammonia-to-amines vertical integration once the new plants stabilise, and pockets of genuine process IP — the ₹220 crore fluorochemicals plant management calls “first and only of its kind.” There is also a regulatory tailwind for responsible nitration players as China constrains hazardous chemistries. But the core evidence cuts the other way: operating margins compressed from 29% in FY21 to 12% in FY26 as Chinese oversupply pressed on phenol spreads and intermediates pricing, and key agrochem volumes went to “essentially zero” when customers destocked. A business whose margins swing that much with import pricing is a cost-and-capacity player, not a fortress — and polycarbonate, the flagship bet, is a product China is also building in bulk.

2. Returns on incremental capital and runway. The trend is the uncomfortable part: ROCE has slid from 44% in FY22 to 11.5% on the June 2026 snapshot, ROE sits at 10%, and profit has fallen four years straight. Management’s defence is that roughly ₹1,800 crore of capital-work-in-progress is on the books earning nothing yet; the guided economics on the polycarbonate chain are a 16–18% IRR with a five-to-five-and-a-half-year payback. The runway itself is genuinely long — ₹11,000 crore to deploy against an Indian PC market that imports most of its 400,000-tonne demand — but the returns on it are a promise, not a record, and the record so far is timelines slipping (nitric acid at 45% utilisation a year after “end of Q2,” polycarbonate drifting from December 2027 to June 2028). Moderate prospective returns, long runway, demonstrated execution risk.

3. Capital allocation for the stage. Coherent and reasonably disciplined, with one large open question. Management is doing what a reinvestment-phase company should: it spent down a net-cash balance sheet as the war chest, funds the build 60:40 debt-to-equity with bank lines tied up, caps debt-to-equity at 1.5x, has not diluted (“will approach the market if at all required”), holds the dividend flat at ₹7.50 rather than raising it mid-build, and promoters have inched their 49.33% stake up, not down. No buybacks in the visible record, which is the right call given negative free cash flow (–₹658 crore in FY26). The quibbles: capex guidance churned within single years (₹1,500 crore → ₹800–1,000 → ₹1,200–1,300 for FY26), and the central bet commits ₹11,000 crore into a value chain where Chinese overcapacity is the stated number-one risk. Rational for the stage; the rationality of the destination depends on a recovery management cannot control.

4. Price. Demanding. As of the June 2026 snapshot the stock trades at ₹1,674 — a ₹22,825 crore market cap and 40.8 times FY26 earnings of ₹551 crore, on a business currently earning 11.5% ROCE and 10% ROE, with a 0.45% dividend yield. The multiple only works if you treat FY26 as the trough: even a full recovery to the FY22 peak profit of ₹1,067 crore would still leave the stock at roughly 21 times, and that peak came in an exceptional cycle. The market — domestic institutions in particular, up from 15.6% to 23.5% of the register in three years — is paying today for the integrated complex of 2028 arriving on schedule and earning its guided returns, when the schedule has already slipped at every checkpoint. That is a price which needs most things to go right.

Sources

• Earnings-call transcripts read (4): Q1 FY26 (14 Aug 2025), Q2/H1 FY26 (14 Nov 2025), Q3/9M FY26 (13 Feb 2026), Q4/FY26 (18 May 2026). From screener/BSE-hosted filings.
• Annual reports read (high-signal sections + targeted full-text reads): FY23, FY24, FY25.
• Financial snapshot: screener.in (consolidated, DEEPAKNTR), logged-out session, fetched 2026-06-07. Note: management’s full-year revenue (₹7,947 crore, excluding ₹91 crore dividend income) and screener’s net-sales figure (₹7,887 crore) differ slightly on definition; both point to FY26 revenue roughly flat-to-down vs FY25.
• Research dump: vault/Sources/Earnings/Deepak Nitrite Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.